Inform Dentist Biologics — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

EasyRheumatoid ArthritisInform Dentist BiologicsSCE Rheumatology

A 50-year-old woman with rheumatoid arthritis is receiving infliximab. She asks whether she needs to mention this treatment when attending her dentist. What is the most appropriate advice?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Inform the dentist about infliximab and show the patient reminder card

Patients receiving infliximab should tell their dentist and show the patient reminder card. This applies even when rheumatoid arthritis is controlled and is not limited to extractions or concurrent bisphosphonate treatment. Biologic therapy affects infection risk and may influence planning if an invasive procedure or active dental infection is present. The patient should also notify the prescribing team about planned dental procedures. She should not stop infliximab autonomously: any interruption must be decided according to the procedure, infection status and specialist advice. Bisphosphonates have separate dental implications, particularly medication-related osteonecrosis of the jaw, but their absence does not remove the need to disclose infliximab treatment.

Reference: Electronic Medicines Compendium. Remicade 100 mg powder for concentrate for solution for infusion, Patient Information Leaflet, section 2: Operations or dental procedures. Revised April 2025. https://www.medicines.org.uk/emc/product/3831/pil